PPARG and cancer: Currently, still under development, several highly promising candidate differentiation and cellular reprograming targets encompassing epigenetics, transcription factors, metabolic and modulators of the cancer stem cells are being evaluated preclinically and clinically as anti-cancer therapeutics (i.e., inhibitors of histone deacetylases (HDACi) (118), micro-RNAs (119) peroxisome proliferator-activated receptor-γ (PPARγ) pathway (120–122), inhibitors of bromodomain-containing protein 4 (BRD4i) (123) among others (115)).